InsidersTradesSigma
Follow the KORU Medical Systems, Inc. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, KORU Medical Systems, Inc. has published 137 public disclosures. Market capitalisation: €152.7m. The latest transaction was reported on 9 September 2026 (Acquisition). Among the most active insiders: Manko Joseph M. Jr.. Every trade is openly available.
137
Insider Decl.
n/a
Thresholds
€492,211
5 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate KORU Medical Systems, Inc. Strong Buy (bullish), based on 5 analysts. Average price target: US$6.60.
30Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 25,758 of 29,064 companies
23.4
score / 100
Value32
Quality15
FCF yld-0.3%
Earn yld-1.5%
EV/EBITDA·
ROE-11%
Gross mgn·
Net mgn-15%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 9 September 2026
Declarations137 total
32,000 shares@ US$3.16Common StockSEC:0001161697-26-000210:0
Canonical exit: 7 Dec 2026 (T+90)
75,000 shares0Common StockSEC:0001161697-26-000191:0
25,483 shares@ US$4.260.058% mcap50.3% of flowCommon StockSEC:0001161697-26-000191:1
25,483 shares@ US$4.26280.056% mcap100.0% of flowCommon StockSEC144:0001972481-26-000245
3,571 sharesCommon StockSEC:0001161697-26-000143:0
3,472 shares0Common StockSEC:0001161697-26-000088:0
3,472 shares0Common StockSEC:0001161697-26-000079:0
3,472 shares@ US$4.324.9% of flowCommon StockSEC:0001161697-26-000080:0
5,208 shares@ US$4.326.6% of flowCommon StockSEC:0001161697-26-000081:0
3,472 shares@ US$4.326.6% of flowCommon StockSEC:0001161697-26-000082:0
3,472 shares@ US$4.326.2% of flowCommon StockSEC:0001161697-26-000083:0
3,472 shares@ US$4.3213.4% of flowCommon StockSEC:0001161697-26-000084:0
5,064 shares0Common StockSEC:0001161697-26-000062:0
5,404 shares0Common StockSEC:0001161697-26-000060:0
15,968 shares0Common StockSEC:0001161697-26-000058:0
770,418 shares0Common StockSEC:0001161697-26-000041:0
76,426 shares0Common StockSEC:0001161697-26-000035:0
2,581 shares0Common StockSEC:0001161697-26-000016:0
2,581 shares@ US$5.819.5% of flowCommon StockSEC:0001161697-26-000013:0
2,581 shares@ US$5.815.2% of flowCommon StockSEC:0001161697-26-000012:0
2,581 shares@ US$5.813.8% of flowCommon StockSEC:0001161697-26-000011:0
3,872 shares@ US$5.815.5% of flowCommon StockSEC:0001161697-26-000010:0
2,581 shares@ US$5.814.2% of flowCommon StockSEC:0001161697-26-000009:0
41,000 shares0Common StockSEC:0001161697-25-000428:0
29,463 shares@ US$4.0833.0% of flowCommon StockSEC:0001161697-25-000367:0
25 of 137 declarations
关于 KORU Medical Systems, Inc.
KORU Medical Systems, Inc.（股票代码：KRMD）是一家总部位于美国的医疗设备公司，在美国纳斯达克上市。对于法语投资者而言，它符合专注于大容量皮下输注解决方案而非药品的利基医疗技术公司的形象。该公司成立于1980年，总部位于新泽西州马瓦。其商业模式以医疗保健服务的一个专业领域为中心，其中易用性、可靠性和患者便利性是关键的差异化因素。（[stockanalysis.com](https://stockanalysis.com/stocks/krmd/company/?utm_source=openai)） KORU Medical开发、制造和商业化以患者为中心的输注系统，用于皮下给药治疗，包括在家庭和门诊护理环境中。其旗舰平台是Freedom System，该系统于1994年首次获得FDA批准。该公司还重点介绍了FreedomEDGE，这是一种注射器/输注系统，专为家庭护理、输注中心和其他医疗环境中的皮下给药而设计。实际上，KORU服务于需要重复或专业治疗给药的治疗领域，重点是便携性、便利性和患者体验。（[investors.korumedical.com](https://investors.korumedical.com/news-events/press-releases/detail/192/koru-medical-systems-reports-preliminary-q4-and-full-year-2025-results-achieves-record-revenue-and-full-year-positive-operating-cash-flow?utm_source=openai)） 从竞争角度来看，KORU在一个专注的利基市场中运营，其长期技术专长和已安装的基础至关重要，但其规模仍远小于全球医疗技术巨头。其竞争优势来自于专业化、应用专业知识以及与制药和护理服务机构合作的能力。公司近期沟通表明商业势头正在改善：2025年，KORU报告了2025财年的收入增长、调整后运营盈利能力改善和正向运营现金流，同时上调了收入指引。该公司还在2025年宣布了一项下一代皮下免疫球蛋白输注协议，并在欧洲展示了临床数据，表明产品开发和更广泛的地域拓展。（[investors.korumedical.com](https://investors.korumedical.com/news-events/press-releases/detail/195/koru-medical-systems-announces-20-fourth-quarter-and-full-year-2025-revenue-growth-positive-adjusted-ebitda-and-initiates-full-year-2026-guidance?utm_source=openai)） 从地理上看，KORU主要以美国为中心，但近期文件和披露显示其具有重要的国际业务活动并对增长做出了贡献。因此，对于法国、比利时和瑞士的投资者而言，KRMD应被视为一家在美国纳斯达克上市的小盘医疗保健公司，涉足专业医疗设备、家庭输注的普及以及皮下给药途径的日益广泛使用。其投资案例最好理解为一个专业的增长故事，由执行力、临床和商业合作以及不断扩展的使用案例驱动，而非医疗保健领域的广泛多元化。（[investors.korumedical.com](https://investors.korumedical.com/sec-filings/all-sec-filings/content/0001161697-26-000107/0001161697-26-000107.pdf?utm_source=openai)）
